Skip to content
Review Open access

Efficacy and safety of icotrokinra (JNJ2113) for moderate-to-severe plaque psoriasis: a systematic review and metaanalysis of randomized controlled trials

2026 · Annals of Middle Eastern Medicine · 0 citations

TL;DR

Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs and offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time.

Abstract

Icotrokinra (JNJ-2113) is a first-in-class targeted oral peptide that selectively binds to the interleukin-23 (IL-23) receptor and blocks IL-23 signaling. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) of Icotrokinra to assess its efficacy and safety versus control in moderate-to-severe plaque psoriasis. We performed a PRISMA-adherent systematic literature search across Scopus, PubMed, and Web of Science from their inception up to January 2026. Screening, data extraction, and risk of bias assessment were made by two independent authors. A meta-analysis was conducted in R with sensitivity and subgroup analyses. We included four studies comprising five RCTs. Oral icotrokinra significantly improved physician-assessed and psoriasis area and severity index (PASI) responses compared with control in RCTs. For Investigator’s Global Assessment (IGA) 0/1, benefit was evident by week 2 (risk ratios (RR) = 3.24%, 95% confidence interval (CI) 1.01–10.46) and remained consistent through week 16 (RR = 7.35%, 95% CI 5.67–9.54), with an overall pooled effect RR = 7.31 (95% CI 6.25–8.55). Complete clearance (IGA 0) emerged from week 8 (RR = 23.65%, 95% CI 6.74–82.95), overall RR = 12.44 (95% CI 6.88–22.51). PASI 75 overall RR = 6.74 (95% CI 5.75–7.91); PASI 90 RR = 14.38; PASI 100 RR = 11.17. PSSD symptom 0 at week 16: 256/1226 vs 9/551 (RR=9.62%, 95% CI 5.14–18.01). Icotrokinra offers rapid and clinically significant improvements in plaque psoriasis, particularly on IGA and PASI, and these responses continue to improve over time; by week 8, complete clearance became significantly more frequent with icotrokinra. Safety outcomes were comparable between icotrokinra and placebo, and there was no meaningful increase in serious adverse events.

Read PDF

Similar papers

Review Open access Jul 2026

Efficacy and Safety of Icotrokinra (an Interleukin-23 Inhibitor) in the Management of Moderate-to-Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis

Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients’ quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effecti...

Z. Siddiqi, Sume Rubab, Faisal Jamal Alashkar et al. · 0 citations
Review Sep 2026

Teprotumumab for Thyroid Eye Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials and Real-World Studies.

TOPIC Teprotumumab is the first FDA-approved biologic for moderate-to-severe thyroid eye disease (TED). Although efficacy has been established in randomized controlled trials (RCTs), real-world studies (RWS) have reported different efficacy and safety patterns, supporting an updated synthesis. CLINICAL RELEVANCE A co...

Ai-Min Sun, Xing Wang, Jun-Yu Wang et al. · 1 citation
Review Open access Sep 2026

Efficacy and Safety of Mirikizumab for Induction and Maintenance of Remission in Ulcerative Colitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Objective: Mirikizumab, a p19-directed anti-interleukin-23 monoclonal antibody, has been evaluated as induction and maintenance therapy for moderately to severely active ulcerative colitis (UC). We conducted a systematic review and meta-analysis of randomized, placebo-controlled trials to quantify its efficacy and safe...

G. Dağcı, A. Sarıca, B. F. Ağargün et al. · 0 citations
Review Open access Oct 2026

Comparative efficacy and safety of treatments for eosinophilic esophagitis: Systematic review and network meta-analysis of randomized controlled trials.

BACKGROUND Eosinophilic esophagitis (EoE) is a chronic immune-mediated disease characterized by esophageal dysfunction and eosinophilic inflammation. Comparative efficacy and safety of therapies remain uncertain. OBJECTIVE To compare efficacy and safety of treatments for EoE in children and adults. METHODS We condu...

Y. Roldan, I. Silang, D. Rayner et al. · 0 citations
Review Oct 2026

Efficacy and safety of guselkumab for inflammatory bowel diseases: a systematic review and meta-analysis of randomized controlled trials.

Crohn's disease and ulcerative colitis are chronic inflammatory bowel diseases (IBDs) driven by the interleukin-23/Th17 pathway. Guselkumab, a selective interleukin-23p19 monoclonal antibody, has shown promise in phase II/III trials. This systematic review and meta-analysis aimed to synthesize its efficacy and safety v...

Z. Shahid, M. Azam, Ahila Ali et al. · 0 citations
Review Open access Sep 2026

The Efficacy and Safety of Palmul-tang for Chemotherapy-Induced Leukopenia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials

Objectives: To evaluate the clinical efficacy and safety of Bazhen Decoction for chemotherapy-induced leukopenia, we analyzed randomized controlled trials (RCTs) in which Palmul-tang (Bazhen Decoction) was administered to patients with chemotherapy-induced leukopenia.Methods: Nine databases were searched for RCTs publi...

Ah-young Choi, Jung-Hun Lee, Sung-mo Kim et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.